NSCLC metastatic/molecular target

 
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 15/11/2019)

EGFR
ZENITH20 Poziotinib (Spectrum)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.
(Currently only cohort 3 and 4)

ALK
Currently no trials

KRAS
Currently no trials

RET
Currently no trials

BRAF
Currently no trials

C-MET
CINC280 (Novartis) -> for 1st line
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer.
(only cohort 7 open)

ROS1
BFAST (Roche)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).
(only cohort D open)

HER2
ZENITH20 Poziotinib (Spectrum)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.
(Currently only cohort 3 and 4)‚Äč